Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Prithviraj Bose

Showing results (1-10 of 224) with videos related to

Pageof 23
Sort By:
Expert Opinion on Orphan Drugs|October 23, 2020
Advances in potential treatment options for myeloproliferative neoplasm associated myelofibrosisPrithviraj Bose
Clinical Advances in Hematology & Oncology : H&O|September 20, 2022
Cases in the management of polycythemia vera: a patient with progressive leukocytosisPrithviraj Bose
Clinical Lymphoma, Myeloma & Leukemia|September 1, 2020
A Young Woman with ThrombocytosisPrithviraj Bose
Current Hematologic Malignancy Reports|March 5, 2024
Management of Patients with Early Myelofibrosis: A Discussion of Best PracticesPrithviraj Bose
Blood|July 3, 2024
Momelotinib for the treatment of myelofibrosisPrithviraj Bose
Oncoscience|January 19, 2018
Ruxolitinib for essential thrombocythemia?Prithviraj Bose, Srdan Verstovsek
Current Hematologic Malignancy Reports|May 26, 2018
Management of Myelofibrosis-Related CytopeniasPrithviraj Bose, Srdan Verstovsek
Expert Opinion on Investigational Drugs|September 29, 2009
Neratinib: an oral, irreversible dual EGFR/HER2 inhibitor for breast and non-small cell lung cancerPrithviraj Bose, Howard Ozer
Leukemia Research Reports|August 27, 2013
Mcl-1 as a Therapeutic Target in Acute Myelogenous Leukemia (AML)Prithviraj Bose, Steven Grant
International Journal of Hematology|October 21, 2019
Mutational profiling in myelofibrosis: implications for managementPrithviraj Bose, Srdan Verstovsek
Pageof 23

Showing results (1-10 of 224) with videos related to

Sort By:
Pageof 23
Expert Opinion on Orphan Drugs|October 23, 2020
Advances in potential treatment options for myeloproliferative neoplasm associated myelofibrosisPrithviraj Bose
Clinical Advances in Hematology & Oncology : H&O|September 20, 2022
Cases in the management of polycythemia vera: a patient with progressive leukocytosisPrithviraj Bose
Clinical Lymphoma, Myeloma & Leukemia|September 1, 2020
A Young Woman with ThrombocytosisPrithviraj Bose
Current Hematologic Malignancy Reports|March 5, 2024
Management of Patients with Early Myelofibrosis: A Discussion of Best PracticesPrithviraj Bose
Blood|July 3, 2024
Momelotinib for the treatment of myelofibrosisPrithviraj Bose
Oncoscience|January 19, 2018
Ruxolitinib for essential thrombocythemia?Prithviraj Bose, Srdan Verstovsek
Current Hematologic Malignancy Reports|May 26, 2018
Management of Myelofibrosis-Related CytopeniasPrithviraj Bose, Srdan Verstovsek
Expert Opinion on Investigational Drugs|September 29, 2009
Neratinib: an oral, irreversible dual EGFR/HER2 inhibitor for breast and non-small cell lung cancerPrithviraj Bose, Howard Ozer
Leukemia Research Reports|August 27, 2013
Mcl-1 as a Therapeutic Target in Acute Myelogenous Leukemia (AML)Prithviraj Bose, Steven Grant
International Journal of Hematology|October 21, 2019
Mutational profiling in myelofibrosis: implications for managementPrithviraj Bose, Srdan Verstovsek
Pageof 23